GlaxoSmithKline News and Research

RSS

New series of human drug targets available to all researchers

The Structural Genomics Consortium (SGC), an Anglo-Canadian charitable consortium of public and private agencies including Oxford University, announced recently that it has delivered its first 50 human and malaria protein structures into the public domain on budget and two months ahead of schedule.

6 Jun 2005

New vaccine against whooping cough is effective in teens and adults

The Journal of the American Medical Association (JAMA) has announced that a study to be published in the June 22/29 issue found that a new vaccine against whooping cough is effective in teens and adults, carriers of the contagious respiratory disease so dangerous to infants.

3 Jun 2005

Tragic death of 5 year old asthma patient was avoidable and due to complacency of health professionals

At a fatal accident inquiry a sheriff has hit out at the "complacency" of health professionals and a drugs manufacturer over the safety of an asthma inhaler steroid.

25 May 2005

Merck cervical cancer virus vaccine performs well

Drugmaker Merck & Co. Inc. on Thursday said its investigational vaccine against a sexually transmitted virus linked to cervical cancer triggered a stronger immune response in young adolescents than in young women in a late-stage trial.

20 May 2005

Cervical cancer virus vaccine appears very promising

Gardasil, a vaccine created by drugmaker Merck & Co which aims to protect against a sexually transmitted virus linked to cervical cancer, triggered a stronger immune response in young adolescents than in young women in a late-stage trial.

19 May 2005

Clues about how alcoholic behavior is “switched” on

As part of an ongoing effort to understand the biochemical basis of alcohol abuse, scientists at the U.S. Department of Energy’s Brookhaven National Laboratory have published two studies on how modulating receptors for dopamine - a chemical “signaler” in the brain’s reward circuits - affects drinking behavior in mice and rats.

9 May 2005

New cervical cancer drug could be a bestseller

New data released yesterday says that a new vaccine that promises to protect against cervical cancer could offer wider resistance to the disease than previously thought.

5 May 2005

Boostrix receives FDA approval as treatment for pertussis

GlaxoSmithKline today announced that its booster vaccine, Boostrix received approval from the United States (U.S.) Food and Drug Administration (FDA).

3 May 2005

Whooping cough makes a comeback

The latest comeback in the health arena is whooping cough and experts are sufficiently concerned for the US government to approve the first whooping cough booster shot meant just for adolescents. The shot will be added to a booster shot against two other diseases, tetanus and diphtheria, that children already get sometime between ages 10 and 18.

3 May 2005

FDA to change regulations regarding side-effect information in drug ads

The Food and Drug Administration is about to make it easier for you to understand both the benefits and risks of a prescription medication, it was revealed at the Second Annual Medical Liaison Seminar sponsored here by Scientific Advantage LLC.

2 May 2005

GlaxoSmithKline to acquire Corixa Corporation

GlaxoSmithKline has announced the execution of a definitive agreement pursuant to which GSK will acquire Corixa Corporation, a developer of innovative products that regulate immunity, based in Seattle, WA (USA).

2 May 2005

Judge calls GlaxoSmithKline 'high-handed' over legal action from Biota

A Supreme Court judge in Melbourne, Australia has described as "high-handed" the delay by global pharmaceutical firm GlaxoSmithKline (GSK) in filing a defence against legal action from Biota Holdings last Friday.

1 May 2005

SkyePharma and GlaxoSmithKline reach agreement on payment of royalties for Paxil CR

SkyePharma has announced that it has entered into an amendment agreement with GlaxoSmithKline (GSK) in respect of Paxil CR. Under the terms of the amendment agreement, GSK will make a one-time payment of approximately $10 million.

28 Apr 2005

EU calls for tougher warnings on antidepressants for kids

A committee of experts in Europe are calling for strong warnings to be placed on two classes of antidepressants, informing doctors and parents of the risk they could pose to children and adolescents.

25 Apr 2005

Breast cancer gene may play a major role in the recurrence of prostate cancer

A gene associated with breast cancer also may play a major role in the recurrence of prostate cancer, according to new research from the University of North Carolina at Chapel Hill School of Medicine and UNC Lineberger Comprehensive Cancer Center.

20 Apr 2005

Rates of cervical cancer could jump fourfold to a million a year by 2050

Deaths from cervical cancer could jump fourfold to a million a year by 2050, mainly in developing countries. This could be prevented by soon-to-be-approved vaccines against the virus that causes most cases of cervical cancer- but there are signs that opposition to the vaccines might lead to many preventable deaths. The trouble is that the human papilloma virus (HPV) is sexually transmitted.

13 Apr 2005

Researchers and drug giant team up to find cure for CJD

The Medical Research Council's Prion Unit, based at University College London, a leading British research group, is joining forces with drugs giant GlaxoSmithKline (GSK) to develop a cure for the disease Creutzfeldt-Jakob Disease (CJD).

12 Apr 2005

Panel in US disputes drug trial allegations

Medical experts have been forced to defend a study conducted in Uganda and called HIVNET 012 that led to the widespread use of a single AIDS drug called nevirapine to protect newborns, after allegations by Dr. Jonathan Fishbein, a National Institutes of Health researcher, that the research was flawed and the conclusions were unfounded.

10 Apr 2005

Race to market cancer vaccine

In a race to market the first vaccine against the virus that causes cervical cancer and genital warts drug manufacturers Merck & Co Inc. and GlaxoSmithKline plc are in head-to-head competition.

7 Apr 2005

Pfizer withdraws Bextra from market

Despite an expert panel stating last month that the three COX-2 drugs Vioxx, Bextra and Celebrex were safe enough to be marketed, the U.S. Food and Drug Administration (FDA) has this week told drug manufacturer Pfizer to remove the drug Bextra from the market and a statement by Pfizer confirms that the European Union regulators have done the same.

7 Apr 2005